AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound having affinity to and/or selectivity for P-selectin and having structure of formula Ia:



or a stereo-isomer thereof represented by the following formula Ib:



wherein:

X ~~is an optional group, which~~ represents -O-, $-OCH_2-$, $\underline{-CH_2-}$, -S-, $-SCH_2-$, -NH- or $-NHCH_2-$;

R^1 represents QR^4, wherein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R^4 represents ~~any substituent comprising at least one carbon atom~~ a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group;

R^2 is a ~~moiety bearing at least one negative charge~~ phosphate, phosphonate, carboxylate, or sulphonate group; and

R^3 is ~~any group~~ OH or YR^5, wherein Y is -O-, $-CH_2-$ or -NH- and R^5 is a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group.

2. (Currently amended) The compound according to claim 1, wherein X is ~~not present or represents -O-~~ $-OCH_2-$.

3. (Currently amended) The compound according to claim 1, wherein Q represents -NH-(C=O)- or -NH-(C=O)-O-.

4. (Currently amended) The compound according to claim 1, wherein R^2 is ~~or comprises~~ a phosphate group.

5. (Currently amended) The compound according to claim 1, wherein R^3 represents OH~~ or YR^5~~, ~~wherein Y is O , CH_2 or NH and R^5 comprises at least one carbon atom~~.

6. (Currently amended) The compound according to claim 1, wherein R^4 ~~comprises an alkyl moiety, an aromatic moiety or a group comprising an electron withdrawing moiety~~ is substituted with a group selected from the group consisting of nitro, -C(O)alkyl, cyano, $-SO_3H$, $-CCl_3$, and $-CF_3$.

7. (Currently amended) The compound according to ~~claim 6~~ claim 1, wherein R^4 is a phenyl or naphthalene group.

8-13.(Canceled)

14. (Currently amended) A composition comprising in a pharmaceutically acceptable carrier a compound according to claim 1 or a ~~derivative~~, salt~~, conjugate,~~ or solvate~~, or multimer~~ thereof.

15. (Currently amended) A method for determining whether a compound is capable of binding to P-selectin or a functional equivalent or P-selectin, comprising contacting and incubating the compound to be tested and a predetermined amount of a compound having affinity to and/or selectivity for P-selectin, represented by the formula Ia,



or a stereo-isomer thereof represented by the formula Ib,



wherein:

X ~~is an optional group, which~~ represents -O-, -OCH_2-, -CH_2-, -S-, -SCH_2-, -NH- or -$NHCH_2$-;

R^1 represents QR^4, wherein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R^4 represents ~~any substituent comprising at least one carbon atom~~ a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group;

R^2 is a ~~moiety bearing at least one negative charge~~ phosphate, phosphonate, carboxylate, or sulphonate group; and

R^3 ~~R' can be any group~~ is OH or YR^5, wherein Y is -O-, -CH_2- or -NH- and R^5 is a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group,

with a predetermined amount of P-selectin or said functional equivalent of P-selectin

and

subsequently determining the amount of the same compound.

16. (Previously presented) A method of treating or inhibiting a disease or condition involving activation and/or overexpression of P-selectin in a mammal inflicted with such a disease, the method comprising administering to the mammal an effective P-selectin inhibiting amount of a composition according to claim 14.

17. (New) The compound according to claim 1, wherein X represents -CH_2-.

18. (New) The compound according to claim 1, wherein Q represents -NH-(C=O)-.

19. (New) The compound according to claim 1, wherein X represents -OCH_2- and Q represents -NH-(C=O)- or -NH-(C=O)-O-.